SEARCH:   Advanced

Blood, 1 March 2007, Vol. 109, No. 5, pp. 1870-1877. Prepublished online as a Blood First Edition Paper on October 17, 2006; DOI 10.1182/blood-2006-06-029850. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2006-06-029850v1 109/5/1870    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Collins, P. W. Articles by Hay, C. R. M. Search for Related Content PubMed PubMed Citation Articles by Collins, P. W. Articles by Hay, C. R. M. Related Collections Hemostasis, Thrombosis, and Vascular Biology Free Research Articles Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation Peter W. Collins1, Sybil Hirsch2, Trevor P. Baglin3, Gerard Dolan4, John Hanley5, Michael Makris6, David M. Keeling7, Ri Liesner8, Simon A. Brown9, Charles R. M. Hay2, and UK Haemophilia Centre Doctors' Organisation 1 University Hospital of Wales and School of Medicine, Cardiff University, United Kingdom; 2 Manchester Royal Infirmary, Manchester, United Kingdom; 3 Addenbrookes Hospital, Cambridge, United Kingdom; 4 Queen's Medical Centre, Nottingham, United Kingdom; 5 Royal Victoria Infirmary, Newcastle, United Kingdom; 6 Hallamshire Hospital, Sheffield, United Kingdom; 7 Oxford Haemophilia Centre, United Kingdom; 8 Great Ormond Hospital, London, United Kingdom; 9 Royal Free Hospital, London, United Kingdom Acquired hemophilia A is a severe bleeding disorder caused by an autoantibody to factor VIII. Previous reports have focused on referral center patients and it is unclear whether these findings are generally applicable. To improve understanding of the disease, a 2-year observational study was established to identify and characterize the presenting features and outcome of all patients with acquired hemophilia A in the United Kingdom. This allowed a consecutive cohort of patients, unbiased by referral or reporting practice, to be studied. A total of 172 patients with a median age of 78 years were identified, an incidence of 1.48/million/y. The cohort was significantly older than previously reported series, but bleeding manifestations and underlying diseases were similar. Bleeding was the cause of death in 9% of the cohort and remained a risk until the inhibitor had been eradicated. There was no difference in inhibitor eradication or mortality between patients treated with steroids alone and a combination of steroids and cytotoxic agents. Relapse of the inhibitor was observed in 20% of the patients who had attained first complete remission. The data provide the most complete description of acquired hemophilia A available and are applicable to patients presenting to all centers. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Acquired hemophilia A: is more better? Joan Cox Gill Blood 2007 109: 1793-1794. [Full Text] [PDF] This article has been cited by other articles: H. Mansouritorghabeh, M. Lak, and W. L. van Heerde Idiopathic Factor VIII Inhibitor Autoantibody in a Man Presented After Accident Clinical and Applied Thrombosis/Hemostasis, October 1, 2009; 15(5): 588 - 590. [Abstract] [PDF] L. Spiezia, L. Meneghetti, F. Dalla Valle, G. Tognin, C. Radu, G. Saggiorato, M. Fadin, E. Zanon, and P. Simioni Potential Role of Thrombelastography in the Monitoring of Acquired Factor VIII Inhibitor Hemophilia A: Report on a 78-year-old Woman With Life-threatening Bleedings Clinical and Applied Thrombosis/Hemostasis, August 1, 2009; 15(4): 470 - 476. [Abstract] [PDF] A. Huth-Kuhne and on behalf of the International Expert Panel on Acq Cautions and caveats to the treatment of acquired hemophilia A Haematologica, August 1, 2009; 94(8): 1181 - 1182. [Full Text] [PDF] P. M. Mannucci and F. Peyvandi Autoimmune hemophilia at rescue Haematologica, April 1, 2009; 94(4): 459 - 461. [Full Text] [PDF] A. Huth-Kuhne, F. Baudo, P. Collins, J. Ingerslev, C. M. Kessler, H. Levesque, M. E. M. Castellano, M. Shima, and J. St-Louis International recommendations on the diagnosis and treatment of patients with acquired hemophilia A Haematologica, April 1, 2009; 94(4): 566 - 575. [Abstract] [Full Text] [PDF] S. G Uzlova, K. G Guria, and G. T. Guria Acoustic determination of early stages of intravascular blood coagulation Phil Trans R Soc A, October 13, 2008; 366(1880): 3649 - 3661. [Abstract] [Full Text] [PDF] M. Franchini and G. Lippi Acquired factor VIII inhibitors Blood, July 15, 2008; 112(2): 250 - 255. [Abstract] [Full Text] [PDF] S. Lacroix-Desmazes, A.-M. Navarrete, S. Andre, J. Bayry, S. V. Kaveri, and S. Dasgupta Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A Blood, July 15, 2008; 112(2): 240 - 249. [Abstract] [Full Text] [PDF] B. Wootla, S. Dasgupta, J. D. Dimitrov, J. Bayry, H. Levesque, J.-Y. Borg, A. Borel-Derlon, D. N. Rao, A. Friboulet, S. V. Kaveri, et al. Factor VIII Hydrolysis Mediated by Anti-Factor VIII Autoantibodies in Acquired Hemophilia J. Immunol., June 1, 2008; 180(11): 7714 - 7720. [Abstract] [Full Text] [PDF] Acquired Hemophilia Journal Watch Oncology and Hematology, March 12, 2007; 2007(312): 5 - 5. [Full Text]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020